Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis.
Int J Parasitol Drugs Drug Resist
; 8(2): 223-228, 2018 08.
Article
em En
| MEDLINE
| ID: mdl-29673889
ABSTRACT
Fungisome® (F), a liposomal amphotericin B (AmB) product, is marketed in India as a safe and effective therapeutic for the parasitic infection visceral leishmaniasis. Its potential in the treatment of cutaneous leishmaniasis (CL), a disfiguring form of the disease affecting the skin, is currently unknown. Here, we report the evaluation of the efficacy of F in the Leishmania major BALB/c murine model of CL, including a head-to-head comparison with the standard liposomal AmB formulation AmBisome® (A). Upon intravenous administration at dose levels of 5, 10 and 15â¯mg/kg of body weight (on days 0, 2, 4, 6 and 8), F showed clear signs of toxicity (at 15â¯mg/kg), while A did not. After complete treatment (day 10), the tolerated doses of 5 and 10â¯mg/kg F had significant antileishmanial activity (ED50â¯=â¯4.0 and 12.8â¯mg/kg for qPCR-based parasite load and lesion size, respectively), although less than that of A at identical doses (ED50â¯=â¯3.0 and 8.8â¯mg/kg). The efficacy of F was inferior compared to A because lower levels of the active agent AmB accumulated within the infected lesion. In conclusion, despite possibly being less safe and efficacious than A at equivalent doses, the moderate in vivo activity of F could indicate a role in the systemic pharmacotherapy of CL.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
3_ND
Base de dados:
MEDLINE
Assunto principal:
Anfotericina B
/
Leishmaniose Cutânea
/
Leishmania major
/
Antiprotozoários
Limite:
Animals
País/Região como assunto:
Asia
Idioma:
En
Revista:
Int J Parasitol Drugs Drug Resist
Ano de publicação:
2018
Tipo de documento:
Article